Cytokinetics (CYTK)

Q: What's priced into Cytokinetics (CYTK) stock?

The evidence tags expectations as stretched, despite the valuation model showing CYTK as cheap versus peers and a small peer premium. The expectations gap is 0.15, but model confidence is low, so the relative valuation signal is uncertain. No fragility gates have fired.

Q: What does the Cytokinetics (CYTK) outlook hinge on?

Over the multi-year view, the key questions are whether MYQORZO can sustain commercial growth across new markets and whether aficamten can continue through clinical and regulatory milestones. A guidance reversal is the main company-specific downside scenario in the evidence. Healthcare-sector strength could support the backdrop if bellwethers continue to report strong results and raise guidance, while weakening employment could increase recession concerns.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$61.23-1.76%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cytokinetics’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	60.72M
EPS	—	-1.433
Annual ending 2026-12-31
Revenue	—	153.21M
EPS	—	-6.027
Annual ending 2027-12-31
Revenue	—	427.42M
EPS	—	-4.517

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage operating expenses effectively to improve results	The company aims to control operating expenses better.	Intact	Operating income worse than -$183.6 million in FY26	Operating income: $-179.172M FY2026-Q2; GAAP. Published target: Operating income better than -$183.6 million in Q1 2026. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-179,172,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 53293715-e237-44f9-81d7-b37fb11c6e3e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful launch and sales growth of Myqorzo	A supporting condition in Cytokinetics's published investment case. The stated target is Sustained sales growth of Myqorzo in Germany and beyond.	Improving	Myqorzo sales fail to grow or decline materially	Qualitative: Germany launch (Jun 2026) & real-world study (Sep 2026) confirm growth trajectory Myqorzo launched in Germany (Jun 2026) and real-world study initiated (Sep 2026), supporting sales growth. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue near $830M to $870M in 2026	A primary condition in Cytokinetics's published investment case. The stated target is >= $830 million and <= $870 million.	Intact	Revenue falls below $830 million in FY26	Revenue: $28.624M FY2026-Q2; GAAP. Published target: >= $830 million and <= $870 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 202628,624,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 53293715-e237-44f9-81d7-b37fb11c6e3e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.52

$-4.68 → $-4.52 · observed estimates

FY2027 revenue$0.43B

$0.39B → $0.43B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.68	$393,385,350	15 / 20
2026-07-25	$-4.68	$393,385,350	15 / 20
2026-07-26	$-4.68	$393,385,350	15 / 20
2026-07-27	$-4.69	$393,385,350	15 / 20
2026-07-28	$-4.69	$393,385,350	15 / 20
2026-07-29	$-4.69	$393,385,350	15 / 20
2026-07-30	$-4.69	$393,385,350	15 / 20
2026-07-31	$-4.69	$393,385,350	15 / 20
2026-08-01	$-4.67	$393,283,445	15 / 16
2026-08-02	$-4.69	$393,385,350	15 / 20
2026-08-03	$-4.67	$393,283,445	15 / 16
2026-08-04	$-4.67	$393,283,445	15 / 16
2026-08-05	$-4.69	$393,385,350	15 / 20
2026-08-06	$-4.69	$393,385,350	15 / 20
2026-08-07	$-4.67	$393,283,445	15 / 16
2026-08-08	$-4.64	$404,460,390	15 / 18
2026-08-09	$-4.64	$404,460,390	15 / 18
2026-08-10	$-4.67	$393,283,445	15 / 16
2026-08-11	$-4.67	$393,283,445	15 / 16
2026-08-12	$-4.67	$393,283,445	15 / 16
2026-08-13	$-4.67	$393,283,445	15 / 16
2026-08-14	$-4.67	$393,283,445	15 / 16
2026-08-15	$-4.67	$393,283,445	15 / 16
2026-08-16	$-4.67	$393,283,445	15 / 16
2026-08-17	$-4.67	$393,283,445	15 / 16
2026-08-18	$-4.67	$393,283,445	15 / 16
2026-08-19	$-4.67	$393,283,445	15 / 16
2026-08-20	$-4.49	$423,565,525	15 / 16
2026-08-21	$-4.49	$423,565,525	15 / 16
2026-08-22	$-4.49	$423,565,525	15 / 16
2026-08-23	$-4.49	$423,565,525	15 / 16
2026-08-24	$-4.49	$423,565,525	15 / 16
2026-08-25	$-4.49	$423,565,525	15 / 16
2026-08-26	$-4.49	$423,565,525	15 / 16
2026-08-27	$-4.49	$423,565,525	15 / 16
2026-08-28	$-4.49	$423,565,525	15 / 16
2026-08-29	$-4.48	$423,565,525	15 / 16
2026-08-30	$-4.48	$423,541,904	15 / 16
2026-08-31	$-4.48	$423,541,904	15 / 16
2026-09-01	$-4.48	$423,541,904	15 / 16
2026-09-02	$-4.48	$423,541,904	15 / 16
2026-09-03	$-4.48	$424,824,808	15 / 16
2026-09-04	$-4.48	$424,824,808	15 / 16
2026-09-05	$-4.48	$424,824,808	15 / 16
2026-09-06	$-4.48	$424,824,808	15 / 16
2026-09-07	$-4.48	$424,824,808	15 / 16
2026-09-08	$-4.48	$424,824,808	15 / 16
2026-09-09	$-4.48	$424,824,808	15 / 16
2026-09-10	$-4.48	$424,824,808	15 / 16
2026-09-11	$-4.48	$424,823,108	15 / 16
2026-09-12	$-4.48	$424,823,108	15 / 16
2026-09-13	$-4.48	$424,823,108	15 / 16
2026-09-14	$-4.48	$424,823,108	15 / 16
2026-09-15	$-4.48	$424,823,108	15 / 16
2026-09-16	$-4.48	$424,823,108	15 / 16
2026-09-17	$-4.48	$424,823,108	15 / 16
2026-09-18	$-4.48	$424,823,108	15 / 16
2026-09-19	$-4.48	$424,823,108	15 / 16
2026-09-20	$-4.48	$424,823,108	15 / 16
2026-09-21	$-4.48	$424,823,108	15 / 16
2026-09-22	$-4.48	$424,823,108	15 / 16
2026-09-23	$-4.48	$424,823,108	15 / 16
2026-09-24	$-4.48	$424,823,108	15 / 16
2026-09-25	$-4.48	$423,613,108	15 / 16
2026-09-26	$-4.48	$423,613,108	15 / 16
2026-09-27	$-4.48	$423,613,108	15 / 16
2026-09-28	$-4.48	$423,613,108	15 / 16
2026-09-29	$-4.48	$423,613,108	15 / 16
2026-09-30	$-4.48	$423,613,108	15 / 16
2026-10-01	$-4.48	$423,613,108	15 / 16
2026-10-02	$-4.48	$423,613,108	15 / 16
2026-10-03	$-4.48	$423,611,941	15 / 16
2026-10-04	$-4.48	$423,594,441	15 / 16
2026-10-05	$-4.48	$423,594,441	15 / 16
2026-10-06	$-4.48	$423,594,441	15 / 16
2026-10-07	$-4.48	$423,594,441	15 / 16
2026-10-08	$-4.48	$423,594,441	15 / 16
2026-10-09	$-4.47	$424,511,241	15 / 16
2026-10-10	$-4.47	$424,511,241	15 / 16
2026-10-11	$-4.47	$424,511,241	15 / 16
2026-10-12	$-4.47	$424,511,241	15 / 16
2026-10-13	$-4.47	$424,511,241	15 / 16
2026-10-14	$-4.47	$424,511,241	15 / 16
2026-10-15	$-4.45	$423,099,869	15 / 16
2026-10-16	$-4.45	$423,099,867	15 / 16
2026-10-17	$-4.45	$423,099,867	15 / 16
2026-10-18	$-4.52	$425,987,845	16 / 16
2026-10-19	$-4.52	$425,987,845	16 / 17
2026-10-20	$-4.52	$425,987,845	16 / 17
2026-10-21	$-4.52	$427,418,608	16 / 17
2026-10-22	$-4.52	$427,418,608	16 / 17
2026-10-23	$-4.52	$427,418,608	16 / 17
2026-10-24	$-4.52	$427,418,608	16 / 17

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	19	3
2026-06-01	20	3
2026-07-01	20	3
2026-08-01	20	2
2026-09-01	20	2
2026-10-01	21	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 21 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 14 · prior Jun 29

$115.00 → $104.00-9.6%

RBC CapitalOct 8 · prior Aug 7

$112.00 → $113.00+0.9%

$0$63.25$126.50

1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage operating expenses effectively to improve resultsOperating income: $-179.172M
Revenue near $830M to $870M in 2026Revenue: $28.624M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-30.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cytokinetics outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-development and commercial-launch story, with potential for growth tied to drug adoption and regulatory progress. The thesis is on watch: MYQORZO’s launch is progressing, but recent financial performance has trailed its industry cohort and the company remains loss-making.

What's priced into Cytokinetics

The evidence tags expectations as stretched, despite the valuation model showing CYTK as cheap versus peers and a small peer premium. The expectations gap is 0.15, but model confidence is low, so the relative valuation signal is uncertain. No fragility gates have fired.

What the fundamentals likely do

Near term, MYQORZO revenue and prescribing activity are growing, while launches and market access are expanding; the company plans launches in five or more additional markets by the first half of 2027. Aficamten has positive topline results in ACACIA-HCM, but its next key milestone is a planned supplemental filing in the fourth quarter of 2026, and that priority is rated mixed. Expenses reflect commercial investment, and guidance was raised; a later cut would damage management credibility, while recent peer misses add some execution risk.

What Cytokinetics hinges on

Over the multi-year view, the key questions are whether MYQORZO can sustain commercial growth across new markets and whether aficamten can continue through clinical and regulatory milestones. A guidance reversal is the main company-specific downside scenario in the evidence. Healthcare-sector strength could support the backdrop if bellwethers continue to report strong results and raise guidance, while weakening employment could increase recession concerns.

Bottom line

The business has visible launch momentum and clinical progress, but it remains loss-making and its recent results have lagged peers. The 1-to-3-year thesis depends on continued execution and regulatory progress, with valuation expectations already described as stretched. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	60.72M
EPS	—	-1.433
Annual ending 2026-12-31
Revenue	—	153.21M
EPS	—	-6.027
Annual ending 2027-12-31
Revenue	—	427.42M
EPS	—	-4.517

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.52

$-4.68 → $-4.52 · observed estimates

FY2027 revenue$0.43B

$0.39B → $0.43B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.68	$393,385,350	15 / 20
2026-07-25	$-4.68	$393,385,350	15 / 20
2026-07-26	$-4.68	$393,385,350	15 / 20
2026-07-27	$-4.69	$393,385,350	15 / 20
2026-07-28	$-4.69	$393,385,350	15 / 20
2026-07-29	$-4.69	$393,385,350	15 / 20
2026-07-30	$-4.69	$393,385,350	15 / 20
2026-07-31	$-4.69	$393,385,350	15 / 20
2026-08-01	$-4.67	$393,283,445	15 / 16
2026-08-02	$-4.69	$393,385,350	15 / 20
2026-08-03	$-4.67	$393,283,445	15 / 16
2026-08-04	$-4.67	$393,283,445	15 / 16
2026-08-05	$-4.69	$393,385,350	15 / 20
2026-08-06	$-4.69	$393,385,350	15 / 20
2026-08-07	$-4.67	$393,283,445	15 / 16
2026-08-08	$-4.64	$404,460,390	15 / 18
2026-08-09	$-4.64	$404,460,390	15 / 18
2026-08-10	$-4.67	$393,283,445	15 / 16
2026-08-11	$-4.67	$393,283,445	15 / 16
2026-08-12	$-4.67	$393,283,445	15 / 16
2026-08-13	$-4.67	$393,283,445	15 / 16
2026-08-14	$-4.67	$393,283,445	15 / 16
2026-08-15	$-4.67	$393,283,445	15 / 16
2026-08-16	$-4.67	$393,283,445	15 / 16
2026-08-17	$-4.67	$393,283,445	15 / 16
2026-08-18	$-4.67	$393,283,445	15 / 16
2026-08-19	$-4.67	$393,283,445	15 / 16
2026-08-20	$-4.49	$423,565,525	15 / 16
2026-08-21	$-4.49	$423,565,525	15 / 16
2026-08-22	$-4.49	$423,565,525	15 / 16
2026-08-23	$-4.49	$423,565,525	15 / 16
2026-08-24	$-4.49	$423,565,525	15 / 16
2026-08-25	$-4.49	$423,565,525	15 / 16
2026-08-26	$-4.49	$423,565,525	15 / 16
2026-08-27	$-4.49	$423,565,525	15 / 16
2026-08-28	$-4.49	$423,565,525	15 / 16
2026-08-29	$-4.48	$423,565,525	15 / 16
2026-08-30	$-4.48	$423,541,904	15 / 16
2026-08-31	$-4.48	$423,541,904	15 / 16
2026-09-01	$-4.48	$423,541,904	15 / 16
2026-09-02	$-4.48	$423,541,904	15 / 16
2026-09-03	$-4.48	$424,824,808	15 / 16
2026-09-04	$-4.48	$424,824,808	15 / 16
2026-09-05	$-4.48	$424,824,808	15 / 16
2026-09-06	$-4.48	$424,824,808	15 / 16
2026-09-07	$-4.48	$424,824,808	15 / 16
2026-09-08	$-4.48	$424,824,808	15 / 16
2026-09-09	$-4.48	$424,824,808	15 / 16
2026-09-10	$-4.48	$424,824,808	15 / 16
2026-09-11	$-4.48	$424,823,108	15 / 16
2026-09-12	$-4.48	$424,823,108	15 / 16
2026-09-13	$-4.48	$424,823,108	15 / 16
2026-09-14	$-4.48	$424,823,108	15 / 16
2026-09-15	$-4.48	$424,823,108	15 / 16
2026-09-16	$-4.48	$424,823,108	15 / 16
2026-09-17	$-4.48	$424,823,108	15 / 16
2026-09-18	$-4.48	$424,823,108	15 / 16
2026-09-19	$-4.48	$424,823,108	15 / 16
2026-09-20	$-4.48	$424,823,108	15 / 16
2026-09-21	$-4.48	$424,823,108	15 / 16
2026-09-22	$-4.48	$424,823,108	15 / 16
2026-09-23	$-4.48	$424,823,108	15 / 16
2026-09-24	$-4.48	$424,823,108	15 / 16
2026-09-25	$-4.48	$423,613,108	15 / 16
2026-09-26	$-4.48	$423,613,108	15 / 16
2026-09-27	$-4.48	$423,613,108	15 / 16
2026-09-28	$-4.48	$423,613,108	15 / 16
2026-09-29	$-4.48	$423,613,108	15 / 16
2026-09-30	$-4.48	$423,613,108	15 / 16
2026-10-01	$-4.48	$423,613,108	15 / 16
2026-10-02	$-4.48	$423,613,108	15 / 16
2026-10-03	$-4.48	$423,611,941	15 / 16
2026-10-04	$-4.48	$423,594,441	15 / 16
2026-10-05	$-4.48	$423,594,441	15 / 16
2026-10-06	$-4.48	$423,594,441	15 / 16
2026-10-07	$-4.48	$423,594,441	15 / 16
2026-10-08	$-4.48	$423,594,441	15 / 16
2026-10-09	$-4.47	$424,511,241	15 / 16
2026-10-10	$-4.47	$424,511,241	15 / 16
2026-10-11	$-4.47	$424,511,241	15 / 16
2026-10-12	$-4.47	$424,511,241	15 / 16
2026-10-13	$-4.47	$424,511,241	15 / 16
2026-10-14	$-4.47	$424,511,241	15 / 16
2026-10-15	$-4.45	$423,099,869	15 / 16
2026-10-16	$-4.45	$423,099,867	15 / 16
2026-10-17	$-4.45	$423,099,867	15 / 16
2026-10-18	$-4.52	$425,987,845	16 / 16
2026-10-19	$-4.52	$425,987,845	16 / 17
2026-10-20	$-4.52	$425,987,845	16 / 17
2026-10-21	$-4.52	$427,418,608	16 / 17
2026-10-22	$-4.52	$427,418,608	16 / 17
2026-10-23	$-4.52	$427,418,608	16 / 17
2026-10-24	$-4.52	$427,418,608	16 / 17

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings